A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENANCE FOR THE TREATMENT OF CROHN’S DISEASE

BACKGROUND: Tolerance to therapy is critical for pts to receive the maximal treatment benefit. In Phase 3 clinical trials for ustekinumab (UST) for moderate to severe Crohn’s disease (CD), UNITI-1 enrolled anti-TNF failures and UNITI-2 enrolled conventional therapy failures. In UNITI-1, 36.4% had pr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Can Assoc Gastroenterol
Egile Nagusiak: Loftus, E V, Sattin, B D, Jacobstein, D, Gasink, C, Sloan, S, Feagan, B G, Colombel, J F
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2018
Gaiak:
Paper Sessions
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508225/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.102
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak